Mathias Worni1, Igor Akushevich1, Rachel Greenup1, Deba Sarma1, Marc D Ryser1, Evan R Myers1, E Shelley Hwang2. 1. Division of Advanced Oncologic and GI Surgery, Department of Surgery, (MW, RG, DS, ESH), Center for Population Health and Aging (IA), Department of Obstetrics and Gynecology (ERM), and Department of Mathematics (MDR), Duke University Medical Center, Durham NC; Department of Visceral Surgery and Medicine, Inselspital, Berne University Hospital and University of Berne, Berne, Switzerland (MW). 2. Division of Advanced Oncologic and GI Surgery, Department of Surgery, (MW, RG, DS, ESH), Center for Population Health and Aging (IA), Department of Obstetrics and Gynecology (ERM), and Department of Mathematics (MDR), Duke University Medical Center, Durham NC; Department of Visceral Surgery and Medicine, Inselspital, Berne University Hospital and University of Berne, Berne, Switzerland (MW). shelley.hwang@duke.edu.
Abstract
BACKGROUND: Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS). METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were performed using inverse probability weights (IPW)-adjusted competing risk analyses for DSS and Cox proportional hazard regression for OS. All tests performed were two-sided. RESULTS: One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone (HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%). CONCLUSIONS: We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.
BACKGROUND: Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS). METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were performed using inverse probability weights (IPW)-adjusted competing risk analyses for DSS and Cox proportional hazard regression for OS. All tests performed were two-sided. RESULTS: One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone (HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%). CONCLUSIONS: We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.
Authors: Laura A Lee; Melvin J Silverstein; Cathie T Chung; Heather Macdonald; Premal Sanghavi; Melinda Epstein; Dennis R Holmes; Howard Silberman; Wei Ye; Michael D Lagios Journal: Am J Surg Date: 2006-10 Impact factor: 2.565
Authors: Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty Journal: J Natl Cancer Inst Date: 2010-04-28 Impact factor: 13.506
Authors: Scarlett Lin Gomez; Daphne Lichtensztajn; Allison W Kurian; Melinda L Telli; Ellen T Chang; Theresa H M Keegan; Sally L Glaser; Christina A Clarke Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Funda Meric; Thomas A Buchholz; Nadeem Q Mirza; Georges Vlastos; Frederick C Ames; Merrick I Ross; Raphael E Pollock; S Eva Singletary; Barry W Feig; Henry M Kuerer; Lisa A Newman; George H Perkins; Eric A Strom; Marsha D McNeese; Gabriel N Hortobagyi; Kelly K Hunt Journal: Ann Surg Oncol Date: 2002-07 Impact factor: 5.344
Authors: Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho Journal: Mol Oncol Date: 2013-07-12 Impact factor: 6.603
Authors: Jennifer L Patnaik; Tim Byers; Carolyn DiGuiseppi; Dana Dabelea; Thomas D Denberg Journal: Breast Cancer Res Date: 2011-06-20 Impact factor: 6.466
Authors: S P D'Angelo; C R Antonescu; D Kuk; L Qin; N Moraco; R C Carvajal; P Chi; M A Dickson; M Gounder; M L Keohan; S Singer; G K Schwartz; W D Tap Journal: Br J Cancer Date: 2013-10-08 Impact factor: 7.640
Authors: Oyewale O Shiyanbola; Brian L Sprague; John M Hampton; Kim Dittus; Ted A James; Sally Herschorn; Ronald E Gangnon; Donald L Weaver; Amy Trentham-Dietz Journal: Cancer Date: 2016-05-31 Impact factor: 6.860
Authors: Marc D Ryser; Laura H Hendrix; Mathias Worni; Yiling Liu; Terry Hyslop; E Shelley Hwang Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Monica Morrow; Kimberly J Van Zee; Lawrence J Solin; Nehmat Houssami; Mariana Chavez-MacGregor; Jay R Harris; Janet Horton; Shelley Hwang; Peggy L Johnson; M Luke Marinovich; Stuart J Schnitt; Irene Wapnir; Meena S Moran Journal: Pract Radiat Oncol Date: 2016-06-24
Authors: Marc D Ryser; Mathias Worni; Elizabeth L Turner; Jeffrey R Marks; Rick Durrett; E Shelley Hwang Journal: J Natl Cancer Inst Date: 2015-12-17 Impact factor: 13.506